MOMO'S BREAKOUT BOARD

[dirkv]

Organovo Holdings, Inc. (ONVO): 1.0600-0.0300 (-2.75%)

52 Week Range 1.0000 - 3.4000


SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today announced that its data on the activity of FXR314 in its proprietary 3D human tissue models of Crohn’s disease and ulcerative colitis will be presented at the Crohn’s and Colitis Congress to be held January 25-27, 2024 in Las Vegas, Nevada.
The invited oral presentation, entitled “Evaluation of the clinical stage FXR agonist FXR314 in human primary cell 3D models of Crohn’s disease and ulcerative colitis”, will be made on Friday, January 26, 2024 at 3:00 PM PST by Dr. Fabrice Piu, Vice President, Research & Development.
“We initially identified a strong benefit of FXR agonism in IBD using our internal 3D models, then moved towards development of what we believe to be a best-in-class FXR agonist, FXR314, to treat IBD,” said Keith Murphy, Organovo's Executive Chairman. “Our 3D human tissue models rely on primary cells isolated from individual donors with disease, and we believe our findings to constitute a translational research “gold standard” far superior and complimentary to preclinical animal models alone. FXR314 shows excellent results in standard preclinical models as well. In this presentation, data from our 3D models of IBD, especially the effect of FXR314 on multiple endpoints of IBD including epithelial barrier function and fibrosis in a wide set of Crohn’s disease and ulcerative colitis donors, will be shown.”
Organovo’s current development program for FXR314 focuses on inflammatory bowel disease, where the drug’s differentiated mechanism of action, as highlighted in Organovo’s recently provided mechanism of action video at http://organovo.com/about, provides substantial promise that the drug’s impact will strongly complement the biology of other successful drugs in ulcerative colitis and Crohn’s disease. Organovo plans to begin enrollment for a proof-of-concept Phase 2 ulcerative colitis study in 1H 2024, with targeted completion in 1H 2025. The drug’s additional promise in liver fibrosis and NASH makes it a strong candidate for development in that area through partnership collaborations with Organovo.
About Organovo
Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company’s lead molecule, FXR314, is on the path for Phase 2 investigation in inflammatory bowel disease and has potential application in metabolic liver disease and oncology. The company has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. For more information visit Organovo's website at www.organovo.com.
Jan 12, 2024 1.0700 1.0900 1.0501 1.0600 1.0600 38,173
Jan 01, 2024 1.1000 1.2700 1.0500 1.0600 1.0600 1,573,500
Dec 01, 2023 1.1500 1.3900 1.0500 1.1100 1.1100 6,634,400
Oct 31, 2023 1.1000 2.0500 1.1000 1.1700 1.1700 5,603,100
Sep 30, 2023 1.2100 1.4300 1.0500 1.0600 1.0600 479,500
Aug 31, 2023 1.2000 1.6400 1.0000 1.2500 1.2500 1,245,100
Jul 31, 2023 1.6500 1.6700 1.1400 1.2000 1.2000 685,800
Jun 30, 2023 1.6200 1.9600 1.6200 1.6700 1.6700 535,400
May 31, 2023 1.7100 1.9500 1.6100 1.6900 1.6900 478,300
Apr 30, 2023 1.9500 2.0300 1.7000 1.7000 1.7000 440,700
Mar 31, 2023 2.2000 2.2500 1.7500 1.9500 1.9500 476,600
Mar 01, 2023 2.3200 2.3700 1.7400 2.1900 2.1900 1,132,600
Feb 01, 2023 1.6000 3.4000 1.6000 2.3700 2.3700 5,776,700
Jan 01, 2023 1.4700 1.8900 1.4000 1.6300 1.6300 638,700
Dec 01, 2022 1.5200 1.9000 1.3700 1.4100 1.4100 470,700
Oct 31, 2022 1.7000 1.7100 1.4500 1.5100 1.5100 392,100
Sep 30, 2022 2.1000 2.2300 1.6000 1.6400 1.6400 523,400
Aug 31, 2022 2.6200 2.8600 1.8700 2.0500 2.0500 3,562,200
Jul 31, 2022 2.9000 3.7200 2.2800 2.3600 2.3600 1,104,600
Jun 30, 2022 1.8800 3.6300 1.7500 2.9400 2.9400 4,779,500
May 31, 2022 2.3900 2.5400 1.7100 1.7700 1.7700 652,500
Apr 30, 2022 2.9200 2.9400 2.2400 2.4100 2.4100 439,900
Mar 31, 2022 3.7200 3.7900 2.8400 2.8700 2.8700 450,800
Mar 01, 2022 3.7300 4.6700 3.3400 3.7600 3.7600 1,061,400
Feb 01, 2022 3.1600 3.6400 2.6500 3.5600 3.5600 834,600
Jan 01, 2022 3.7300 4.4800 2.5600 3.1200 3.1200 1,288,000
Dec 01, 2021 4.8600 5.2000 3.6300 3.6300 3.6300 1,480,200
Oct 31, 2021 6.1800 6.5900 4.4100 4.7900 4.7900 1,478,300
Sep 30, 2021 6.7800 6.9700 5.8800 6.2100 6.2100 1,031,100
Aug 31, 2021 7.7100 8.1300 6.5000 6.8000 6.8000 950,200
Jul 31, 2021 7.5800 8.3000 6.0500 7.6600 7.6600 1,757,000
Jun 30, 2021 9.4700 9.5600 7.2600 7.6700 7.6700 1,186,900
May 31, 2021 9.3700 9.8900 7.7100 9.4000 9.4000 4,603,200
Apr 30, 2021 8.5600 11.2500 6.5000 9.4000 9.4000 9,836,900
Mar 31, 2021 10.0300 10.4200 7.5300 8.5400 8.5400 2,893,200
Mar 01, 2021 13.3300 14.0900 8.2400 9.6400 9.6400 5,366,500
Feb 01, 2021 12.7500 23.9200 11.0300 12.7500 12.7500 10,810,700